3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
11
Motor Activity
3
Osteoporosis
2
Neoplasms
2
Urinary Incontinence
1
Urinary Bladder Neoplasms
1
Stroke
1
Signs and Symptoms
1
Sarcopenia
1
Rectal Neoplasms
1
Pelvic Floor Disorders
1
Obesity
1
Neoplasm Metastasis
1
Kidney Diseases
1
Hypertension
1
Heart Failure
1
Head and Neck Neoplasms
1
Frailty
1
Diabetes Mellitus
1
Colorectal Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Transitional Cell
1
Arthritis
1
Interventions
Docetaxel
35
pembrolizumab
32
Nivolumab
27
enzalutamide
20
Prednisone
20
Sunitinib
16
Cyclophosphamide
16
aldesleukin
14
Zoledronic Acid
13
Interleukin-2
13
Gemcitabine
13
Bevacizumab
13
Specimen Handling
12
Ipilimumab
12
Radiosurgery
11
Everolimus
11
Androgen Antagonists
11
Abiraterone Acetate
11
fludarabine
10
Sorafenib
10
Radiotherapy
10
Paclitaxel
10
Magnetic Resonance Spectroscopy
10
pazopanib
9
abiraterone
9
Doxorubicin
8
Carboplatin
8
Biopsy
8
avelumab
7
temsirolimus
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Resistance Training
×
Genitourinary
×
Clear all
NCT02730338
2024-11-27
INTERVAL
Movember Foundation
Phase NA
Active not recruiting
866 enrolled